Comparing Guardian Pharmacy Services (NYSE:GRDN) & SCYNEXIS (NASDAQ:SCYX)

Guardian Pharmacy Services (NYSE:GRDN) and SCYNEXIS (NASDAQ:SCYX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Guardian Pharmacy Services and SCYNEXIS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardian Pharmacy Services	0	2	7	0	2.78
SCYNEXIS	1	0	1	0	2.00

Guardian Pharmacy Services presently has a consensus target price of $42.83, suggesting a potential upside of 1.44%. SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 467.38%. Given SCYNEXIS’s higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Guardian Pharmacy Services.

Volatility & Risk

Guardian Pharmacy Services has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares Guardian Pharmacy Services and SCYNEXIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guardian Pharmacy Services	3.64%	30.72%	15.99%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Earnings and Valuation

This table compares Guardian Pharmacy Services and SCYNEXIS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardian Pharmacy Services	$1.45 billion	1.45	$49.22 million	$0.83	50.87
SCYNEXIS	$20.60 million	2.04	-$8.61 million	($3.84)	-1.10

Guardian Pharmacy Services has higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

54.4% of SCYNEXIS shares are owned by institutional investors. 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Guardian Pharmacy Services beats SCYNEXIS on 10 of the 14 factors compared between the two stocks.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.